Costs of intensive treatment and follow-up of patients with multiple myeloma
| Autor: | C. A. Uyl-De Groot, Gert J. Ossenkoppele, I. Buijt, Peter C. Huijgens |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Melphalan Cancer Research medicine.medical_specialty Cyclophosphamide medicine.medical_treatment Dexamethasone Antineoplastic Combined Chemotherapy Protocols medicine Humans Pharmacology (medical) Leukapheresis Multiple myeloma Aged Retrospective Studies Pharmacology Chemotherapy business.industry Hematopoietic Stem Cell Transplantation Health Care Costs Middle Aged medicine.disease Combined Modality Therapy Hematopoietic Stem Cell Mobilization Surgery Peripheral stem cell transplantation Transplantation Methotrexate Oncology Doxorubicin Vincristine Procarbazine Costs and Cost Analysis Health Services Research Multiple Myeloma business Busulfan Follow-Up Studies medicine.drug |
| Zdroj: | Anti-Cancer Drugs. 9:889-898 |
| ISSN: | 0959-4973 |
| DOI: | 10.1097/00001813-199811000-00008 |
| Popis: | In a retrospective study, we calculated the treatment and follow-up costs of patients with newly diagnosed multiple myeloma. The total treatment programme consisted of eight phases: VAD or VAMP chemotherapy, follow-up I, high-dose melphalan followed by transplantation of whole blood, follow-up II, collection of peripheral blood progenitor cells by leukapheresis, follow-up III, high-dose chemotherapy (busulfan/cyclophosphamide) followed by reinfusion of peripheral stem cells and follow-up IV (until 3 months from hospital discharge after peripheral stem cell transplantation). For each phase the average costs were calculated for all patients who were on treatment/follow-up in each particular phase. The total average cumulative costs of treatment and follow-up of all patients amounted to US$49850. Considering only the patients who completed the total treatment programme as it was scheduled, the average total treatment and follow-up costs were US$44800. The average costs of treatment and follow-up of patients who did not complete the programme as it was scheduled (patients who died, patients who were withdrawn from treatment and patients who received additional treatment) were US$57025. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|